abrdn Life Sciences Investors closed at $18.34 on Nov 12, down 3.22%, 19.1% below its 52-week closing high. Volume of 91.7K shares was 0.84× its 20-day average (close to normal).
Split-adjusted performance: +7.0% over one month, +0.8% over six months, +9.4% over one year.
Short interest was 182.2K shares at the Oct 30 settlement, down 5.4% from the prior report (0.6% of float, 1.7 days to cover).
No recent articles focused on abrdn Life Sciences Investors.
Quick answers
What does abrdn Life Sciences Investors do?
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies.
What is HQL's market cap?
$557.68M, based on the Nov 12 close of $18.34.
Does abrdn Life Sciences Investors pay a dividend?
Yes. The latest regular dividend was $0.62 per share (ex-date Aug 24), an annualised yield of 13.52%.
How much of HQL is sold short?
182.2K shares, 0.6% of float, as of Oct 30, 2026.
About abrdn Life Sciences Investors
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
